Shares of Haemonetics surged +12.4% to $114.33 Thursday after CSL, one of the world's largest plasma collectors, said it expects to equip all of its U.S. plasma centers with Haemonetics' latest blood-plasma collection devices by the end of 2027. The announcement transforms what was an ambiguous supply deal into something that looks like a blockbuster comeback — and the market is pricing it in fast.
• A Lost Customer Returns — With 300+ Centers on the Line. This deal brings the companies back together after their previous supply contract ended in mid-2022.
In the interim, CSL adopted a competitor's plasma collection systems across its U.S. network of more than 300 donation centers, completing that rollout in mid-2025. Now, barely a year later, CSL is switching again. When CSL walked away, the lost contract represented $117 million in annual revenue, or 11.8% of Haemonetics' total. Winning that volume back at 300+ centers would meaningfully move a company that generated $524 million in plasma revenue in fiscal 2026.
• The Fine Print Still Favors CSL. The supply agreement is non-exclusive and does not contain minimum purchase commitments.
Haemonetics itself noted that the scope and timing of the rollout remain subject to change. In other words, CSL can slow down, scale back, or supplement with a competitor's equipment at any time. Investors cheering a full-fleet conversion should remember that today's "expectation" is not a binding order.
• Haemonetics Isn't Changing Its Own Numbers — Yet. The company stated it is not updating its previously issued fiscal 2027 guidance at this time.
It expects to provide a financial-impact update during its second fiscal quarter earnings call in November 2026. That gap between the stock's euphoria and management's caution is telling. The technology — which Haemonetics says can deliver mid-single-digit improvements in plasma volume at a lower cost-per-liter — may have won the technical evaluation, but the revenue ramp is still months away from showing up in results.
• The Stock Has Already Priced In a Lot of Good News. Haemonetics traded near $90 when the initial agreement was disclosed in August; that announcement alone sent shares up about 16% in a single day. Today's further 12% pop means the stock has gained roughly 27% in under two months on a deal that has generated zero incremental revenue so far. Plasma revenue actually fell 2% in fiscal 2026, driven by lower North America volumes tied to the original CSL departure. The November earnings call will be the first real test of whether the market's optimism matches the math.